The impact of clinical risk assessment versus PAM-50 ROR score on prognosis and therapeutic decision making in patients with hormone-receptor positive early stage breast cancer
Devyatko, Y; Filipits, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, C; Fitzal, F; Steger, G; Gray, B; Ferree, S; Fesl, C; Soelkner, L; von Minckwitz, G; Gnant, M CANCER RES. 2019; 79(4):
Vergleich der Hochtontherapie und der TENS Therapie bei chemotherapieinduzierter Polyneuropathie – Projekt HIT-CIPN – Studienprotokoll eines RCT
Johansson T; Schaffler-Schaden D; Herfert J; Sassmann R; Gampenrieder SP; Rinnerthaler G; Lampl K; Rieder F; Flamm M; Greil R; Niebauer J DOI: 10.3205/19degam158. 2019; -53. Kongress für Allgemeinmedizin und Familienmedizin. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) _x000D_ ; 12.-14.09.2019; Erlangen.
A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial
Gampenrieder, S; Angela, R; Rinnerthaler, G; Hackl, H; Steiner, M; Pulverer, W; Weinhaeusel, A; Klinglmayr, E; Karl, T; Ilic, S; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R CANCER RES. 2019; 79(4):
Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial)
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Voskova, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R CANCER RES. 2019; 79(4):
Antihormonal treatment with or without whole breast irradiation in low risk breast cancer patients after breast conserving surgery: 10-year results of the ABCSG 8A trial
Fastner, G; Sedlmayer, F; Widder, J; Metz, M; Geinitz, H; Kapp, K; Solkner, L; Greil, R; Jakesz, R; Gnant, M BREAST. 2019; 44: S79-S79.
Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Papakonstantinou, A; Matikas, A; Hellstrom, M; Johansson, H; Steger, G; Greil, R; Loibl, S; Gnant, M; Moebus, V; Untch, M; Foukakis, T; Bergh, J ANN ONCOL. 2019; 30: 86-+.
The melastatin-like Transient-Receptor-Potential-7 protein regulates Cyclooxygenase-2 expression in human myeloid leukemia cells
Hampe, S; Nadolni, W; Holting, K; Fraticelli, M; Addington, L; Steinritz, D; Chubanov, V; Boekhoff, I; Breit, A; Greil, R; Gudermann, T; Zierler, S ACTA PHYSIOL. 2019; 227:
POSTTRANSPLANT OUTCOMES IN ALLOGENEIC AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN AUSTRIA IN COMPARISON TO THE EBMT BENCHMARK: A RETROSPECTIVE ANALYSIS OF THE AUSTRIAN SCT REGISTRY (ASCTR) 2000-2017
Bohm, A; Lindner, B; Rabitsch, W; Kalhs, P; Worel, N; Clausen, J; Nachbaur, D; Neumeister, P; Panny, M; Keil, F; Russ, G; Eder, S; Isak, E; Zojer, N; Burger, S; Greinix, H TRANSPL INT. 2019; 32: 20-20.
Therapy line and associated predictors of response to PD-1/PD-L1 inhibitor monotherapy in advanced NSCLC – a retrospective bi-centric cohort study
Lang, D; Huemer, F; Rinnerthaler, G; Horner, A; Wass, R; Brehm, E; Akbari, K; Granitz, M; Hutarew, G; Kaiser, B; Greil, R; Lamprecht, B WIEN KLIN WOCHENSCHR. 2019; 131(19-20): 521-522.
Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry
Gampenrieder, SPP; Rinnerthaler, G; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R ANN ONCOL. 2019; 30: 126-+.
